Tremelimumab

Generic Name
Tremelimumab
Brand Names
Imjudo, Tremelimumab AstraZeneca
Drug Type
Biotech
Chemical Formula
-
CAS Number
745013-59-6
Unique Ingredient Identifier
QEN1X95CIX
Background

Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tu...

Indication

Tremelimumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma in combination with durvalumab. It is also indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor...

Associated Conditions
Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC)
Associated Therapies
-
© Copyright 2024. All Rights Reserved by MedPath